Radioisotope producer Nordion International has settled a disputewith a Canadian government agency that had stalled the constructionof nuclear reactors dedicated to producing molybdenum-99, theraw material for technetium. Nordion, of Kanata, Ontario,
Radioisotope producer Nordion International has settled a disputewith a Canadian government agency that had stalled the constructionof nuclear reactors dedicated to producing molybdenum-99, theraw material for technetium. Nordion, of Kanata, Ontario, announcedlast week that it has signed a 20-year agreement with Atomic Energyof Canada Ltd. to fund the construction of two new reactors atAECL's Chalk River facility.
AECL supplies Nordion with molybdenum-99, which Nordion refinesand distributes to radiopharmaceutical customers, who use it tocreate technetium generators. AECL several years ago began buildinga new reactor as a backup to its existing National Research Universalfacility, which provides over 80% of the world's supply of molybdenum.AECL stopped work on the project in 1993, however, in a disputewith Nordion over the terms of a contract that stipulates howmuch AECL should be paid for its radioisotopes (SCAN 6/7/95 and11/17/93).
Last week's agreement resolved the dispute and should enablenuclear medicine practitioners to sleep easier. The first of AECL'stwo identical Maple reactors will begin operations in 1999, withthe second reactor scheduled to go online a year later. The NRUfacility will be decommissioned once the Maple reactors are completed.
The project will cost $140 million, with $100 million financedby an interest-free loan from the Canadian government. Nordionhas said that it will probably have to raise the price of molybdenumto pay for the project, an eventuality that most in the nuclearmedicine community have accepted in exchange for a stable supplyof technetium (SCAN 1/17/96).
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.